Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix or Leuprolide

Fri, 29 Aug 2025 12:04:04 +0000

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.